Do analysts recommend CNSP or PTPI?

CNS Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 294.48%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CNSP or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts rate PTIX or PTPI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PTIX or PTPI more profitable?

Atrinsic's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Petros Pharmaceuticals N/A -78.22% -23.50%

Which has higher valuation and earnings, PTPI or BPTSY?

Petros Pharmaceuticals has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Petros Pharmaceuticals $5.11M 0.03 -$8.16M -$1.64 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is PTPI or BPTSY more profitable?

Biophytis' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% Biophytis N/A N/A N/A

Which has higher valuation and earnings, VRAX or PTPI?

Virax Biolabs Group has higher earnings, but lower revenue than Petros Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 250.40 -$6.06M N/A N/A Petros Pharmaceuticals $5.11M 0.03 -$8.16M -$1.64 N/A

Is VRAX or PTPI more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Petros Pharmaceuticals N/A -78.22% -23.50%

Petros Pharmaceuticals (PTPI) Competitors

$0.0050 0.00 (0.00%)

As of 07/2/2026 03:54 PM Eastern

Compare

PTPI vs. CNSP, PTIX, LIPO, BPTSY, and VRAX

Should you buy Petros Pharmaceuticals stock or one of its competitors? MarketBeat compares Petros Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Petros Pharmaceuticals include CNS Pharmaceuticals (CNSP), Atrinsic (PTIX), Lipella Pharmaceuticals (LIPO), Biophytis (BPTSY), and Virax Biolabs Group (VRAX). These companies are all part of the "pharmaceutical products" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CNS Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 294.48%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CNS Pharmaceuticals has a beta of 3.06, indicating that its stock price is 206% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market.

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

In the previous week, CNS Pharmaceuticals' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Petros Pharmaceuticals	Neutral

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Atrinsic?

Atrinsic (NASDAQ:PTIX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Atrinsic has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market.

Atrinsic has higher earnings, but lower revenue than Petros Pharmaceuticals. Atrinsic is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A

Atrinsic's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

In the previous week, Atrinsic's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
Petros Pharmaceuticals	Neutral

Summary

Petros Pharmaceuticals beats Atrinsic on 7 of the 10 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Lipella Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Lipella Pharmaceuticals has lower revenue, but higher earnings than Petros Pharmaceuticals. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A
Lipella Pharmaceuticals	$536.36K	1.12	-$5.02M	-$2.42	N/A

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Petros Pharmaceuticals has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Petros Pharmaceuticals' return on equity of -78.22% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%

Petros Pharmaceuticals has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Lipella Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Lipella Pharmaceuticals	Neutral

Summary

Petros Pharmaceuticals beats Lipella Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Biophytis?

Petros Pharmaceuticals (NASDAQ:PTPI) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Biophytis' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Biophytis	N/A	N/A	N/A

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Biophytis	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Petros Pharmaceuticals has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Petros Pharmaceuticals beats Biophytis on 4 of the 7 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Virax Biolabs Group's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

In the previous week, Virax Biolabs Group had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Petros Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Petros Pharmaceuticals	Neutral

Virax Biolabs Group has higher earnings, but lower revenue than Petros Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	250.40	-$6.06M	N/A	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Virax Biolabs Group has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe Virax Biolabs Group is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Virax Biolabs Group beats Petros Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTPI vs. The Competition

Export

Metric	Petros Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$156K	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.00	1.66	28.02	24.70
Price / Sales	0.03	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.00	8.17	10.96	6.46
Net Income	-$8.16M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

Petros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTPI Petros Pharmaceuticals	N/A	$0.01 flat	N/A	-85.7%	$156K	$5.11M	N/A	20	Gap Up
CNSP CNS Pharmaceuticals	3.1095 of 5 stars	$4.68 -2.1%	$20.00 +327.4%	-54.1%	$6.99M	N/A	N/A	5
PTIX Atrinsic	N/A	$0.35 -10.7%	N/A	-93.2%	$634K	N/A	N/A	2	Gap Up
LIPO Lipella Pharmaceuticals	N/A	$0.13 +13.3%	N/A	-83.3%	$601K	$536.36K	N/A	4	Gap Up
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, PTIX, LIPO, BPTSY, and VRAX

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Atrinsic?

Summary

How does Petros Pharmaceuticals compare to Lipella Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Biophytis?

Summary

How does Petros Pharmaceuticals compare to Virax Biolabs Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, PTIX, LIPO, BPTSY, and VRAX

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Do insiders & institutionals have more ownership in CNSP or PTPI?

Do analysts recommend CNSP or PTPI?

Which has more risk and volatility, CNSP or PTPI?

Is CNSP or PTPI more profitable?

Does the media prefer CNSP or PTPI?

Which has stronger valuation & earnings, CNSP or PTPI?

Summary

How does Petros Pharmaceuticals compare to Atrinsic?

Do insiders and institutionals hold more shares of PTIX or PTPI?

Do analysts rate PTIX or PTPI?

Which has more volatility & risk, PTIX or PTPI?

Which has higher earnings & valuation, PTIX or PTPI?

Is PTIX or PTPI more profitable?

Does the media favor PTIX or PTPI?

Summary

How does Petros Pharmaceuticals compare to Lipella Pharmaceuticals?

Which has stronger earnings and valuation, PTPI or LIPO?

Do institutionals & insiders believe in PTPI or LIPO?

Is PTPI or LIPO more profitable?

Which has more risk and volatility, PTPI or LIPO?

Does the media favor PTPI or LIPO?

Summary

How does Petros Pharmaceuticals compare to Biophytis?

Is PTPI or BPTSY more profitable?

Does the media prefer PTPI or BPTSY?

Which has higher valuation and earnings, PTPI or BPTSY?

Which has more risk and volatility, PTPI or BPTSY?

Do insiders & institutionals hold more shares of PTPI or BPTSY?

Summary

How does Petros Pharmaceuticals compare to Virax Biolabs Group?

Is VRAX or PTPI more profitable?

Does the media favor VRAX or PTPI?

Which has higher valuation and earnings, VRAX or PTPI?

Do institutionals and insiders believe in VRAX or PTPI?

Which has more volatility and risk, VRAX or PTPI?

Do analysts rate VRAX or PTPI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools